On March 6, the Financial Associated Press reported (Editor Zhao Hao) that the Danish pharmaceutical company$Novo-Nordisk A/S (NVO.US)$is following its American counterpart Eli Lilly and Co in establishing official channels for discounted sales of the "miracle weight loss drug" Wegovy (Semaglutide) in the USA.

On Wednesday (March 5) local time, Novo-Nordisk A/S launched the "NovoCare" pharmacy, providing convenient direct home delivery services for patients. All doses—0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg of Wegovy—can be paid for in cash at a price of just $499 per month.

Novo-Nordisk A/S stated that this offer is available for patients without Insurance or eligible patients with commercial insurance that does not cover obesity medications. In comparison, the price of Wegovy for uninsured patients in the USA is about $1,350 per month, while the NovoCare price is less than half.

Dave Moore, a senior executive at Novo-Nordisk A/S, stated, "With the NovoCare pharmacy, both patients and prescribers can access all doses of authentic, FDA-approved Wegovy at a lower cost."

A press release specifically mentioned that the FDA officially lifted the shortage status of semaglutide last month, allowing Novo-Nordisk A/S to now meet the medication needs of patients across the USA.

This decision means that compounding pharmacies will be prohibited from producing cheaper generic injectables, and customers in need will have to purchase the "genuine" products from Novo-Nordisk A/S.

As of the time of publication, Novo-Nordisk A/S's stock price has risen by over 3% in intraday trading.

There is a Business related to the compound GLP-1 weight loss injection.$Hims & Hers Health (HIMS.US)$The stock price closed up nearly 1%.

Last month, $Eli Lilly and Co (LLY.US)$The price of Zepbound has been reduced by about 50 dollars, with the price of the 2.5 mg and 5 mg vial of Zepbound now priced at 349 dollars and 499 dollars per month, respectively, overall lower than the prices of Novo-Nordisk A/S's competitors.

Editor/ping